Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginsenoside Rg3 H oral drops in advanced non-small cell lung cancer
CTR20160561Phase 2Active
- Sponsor
- Shandong Green Leaf Natural Medicine Research and Development
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ginsenoside Rg3 in non-small cell lung cancer (NSCLC), sponsored by Shandong Green Leaf Natural Medicine Research and Development. Started Dec 2016; status: active.
02
Drugs
ginsenoside Rg3
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20160561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160561.